MedChemExpress - Model Ziltivekimab - 2226654-05-1
Ziltivekimab (COR-001) is a humanized monoclonal antibody against IL-6 that effectively reduces serum CRP levels. Ziltivekimab possesses anti-inflammatory activity and can be used in research related to chronic systemic inflammation associated with chronic kidney disease (CKD) and cardiovascular diseases such as atherosclerosis[1][2].MCE products for research use only. We do not sell to patients.
Ziltivekimab
MCE China：Ziltivekimab
Brand：MedChemExpress (MCE)
Cat. No.HY-P99505
CAS：2226654-05-1
Synonyms：COR-001
Purity：99.75%
Storage：Please store the product under the recommended conditions in the Certificate of Analysis.
Shipping：Shipping with dry ice.
Description：Ziltivekimab (COR-001) is a humanized monoclonal antibody against IL-6 that effectively reduces serum CRP levels. Ziltivekimab possesses anti-inflammatory activity and can be used in research related to chronic systemic inflammation associated with chronic kidney disease (CKD) and cardiovascular diseases such as atherosclerosis.
In Vivo：Ziltivekimab (皮下注射，每 4 周 1 次 共 24 周) 可显著降低参与刺激动脉粥样硬化血栓形成过程的各种生物标志物 (如 hsCRP (高敏C反应蛋白)、纤维蛋白原、血清淀粉样蛋白 A、结合珠蛋白、分泌型磷脂酶 A2 和脂蛋白 (a))，这些标志物也与全身炎症相关[4]。
IC50 & Target：IL-6
Species：Humanized
Isotype：Human IgG1 kappa
Recommend Isotype Controls：Human IgG1 kappa, Isotype Control
Hot selling product：BIM-23056 | Glycitin | Lipoprotein lipase | Wu-5 | α-Arbutin | Ras Antibody | Nagilactone B | H3K4(Me3) (1-20) | Phosphoglycerate kinase | CREBtide
Trending products：Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides
References：
[1]. Kristen L Nowak, et al. A Phase 1 Randomized Dose-Escalation Study of a Human Monoclonal Antibody to IL-6 in CKD. Kidney360. 2020 Dec 4;2(2):224-235. [Content Brief]
[2]. Ridker PM. From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction? Cardiovasc Res. 2021 Sep 28;117(11):e138-e140. [Content Brief]
[3]. Gluba-Brzózka A, et al. Emerging Anti-Atherosclerotic Therapies. Int J Mol Sci. 2021 Nov 9;22(22):12109. [Content Brief]
Brand introduction:
• MCE (MedChemExpress) has a global exclusive compound library of more than 200 kinds, and we are committed to providing the most comprehensive range of high-quality small molecule active compounds for scientific research customers around the world；
• More than 50,000 highly selective inhibitors and agonists are involved in various popular signaling pathways and disease areas；
• The products cover a variety of recombinant proteins, peptides, commonly used kits, more PROTAC, ADC and other characteristic products, widely used in new drug research and development, life science and other scientific research projects；
• Provide virtual screening, ion channel screening, metabolomics analysis detection analysis, drug screening and other professional technical services；
• It has a professional experimental center and strict quality control and verification system；
• Provide LC/MS, NMR, HPLC, chiral analysis, elemental analysis and other quality inspection reports to ensure the high purity and high quality of products；
• The biological activity of the products has been verified by the experiments of customers in various countries；
• A variety of top journals such as Nature, Cell, Science and pharmaceutical patents have included the scientific research results of MCE customers；
• Our professional team tracks the latest pharmaceutical and life science research and provides you with the latest active compounds in the world；
• It has established long-term cooperation with the world's major pharmaceutical companies and well-known scientific research institutions。